Monte Rosa Therapeutics (GLUE) AI Stock Analysis

• Market Cap: $1.84B
• Dividend Yield: N/A
• Average Volume (3M): 2.11M
• Price to Earnings (P/E): 77.6
• Beta (1Y): 1.57
• Revenue Growth: 1112.27%
• EPS Growth: N/A
• Country: US
• Employees: 142
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 76,242,760
• 10 Day Avg. Volume: 4,096,238
• 30 Day Avg. Volume: 2,106,900
• PEG Ratio: 0.11
• Price to Book (P/B): 2.30
• Price to Sales (P/S): 6.78
• P/FCF Ratio: 13.50
• Enterprise Value/Market Cap: 0.24
• Enterprise Value/Revenue: 2.44
• Enterprise Value/Gross Profit: 2.47
• Enterprise Value/Ebitda: 22.62
• 1Y Price Target: $33.80
• Price Target Upside: 40.37% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -1.42
• Revenue Forecast (FY): $51.42M

• Rating: 75 Outperform
• Price Target: $28.00 ▲(16.28% Upside)

The score is driven primarily by the sharp improvement in financial performance—especially strong operating/free cash flow and a swing to profitability—supported by constructive technical momentum. These strengths are tempered by a high P/E valuation and dilution risk from the recent equity raise, even as the financing improves runway and supports continued clinical development.

Positive Factors

Cash generation

Sustained positive operating and free cash flow materially improves Monte Rosa's ability to fund multiple clinical programs without immediate dilutive raises. Strong cash conversion enhances strategic optionality for R&D, partnerships, and regulatory milestones over the next several years.

Strategic partnerships

A large Novartis collaboration validates the QuEEN molecular glue platform and supplies non-dilutive capital and development resources. Deep pharma ties accelerate clinical programs, enhance commercialization pathways, and strengthen the company’s credibility with payers and partners long term.

Clinical validation

Robust biomarker suppression and a clean safety profile for MRT-8102 indicate strong target engagement and translational potential, materially de-risking development. Positive human pharmacology supports broader indications and bolsters partner interest and regulatory strategy over multiple development cycles.

Negative Factors

Profitability volatility

The recent swing to profit follows multi-year losses, highlighting earnings volatility tied to lumpier milestone and collaboration revenue. If revenue recognition or trial outcomes reverse, margins can deteriorate quickly, making sustained profitability contingent on repeatable commercial or partnership wins.

Equity dilution risk

While the $300M raise extends runway, it increases outstanding shares and can dilute existing owners’ economic and voting stakes. Biotech firms often require further financings pre-commercialization, so dilution risk remains a structural constraint on per-share upside until sustainable product revenues appear.

Revenue concentration

As a clinical-stage company, revenue depends on upfronts, reimbursements and milestone timing from partners, producing lumpy cash flows. Lack of commercial products means long-term revenue growth and margin sustainability hinge on partners’ development success and eventual commercialization decisions.

Monte Rosa Therapeutics Business Overview & Revenue Model

Company Description

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Monte Rosa Therapeutics generates revenue primarily through the development and commercialization of its proprietary small molecule degraders. The company may enter into licensing agreements, collaborations, or partnerships with larger pharmaceutical companies to co-develop and commercialize its drug candidates. Revenue can be obtained from upfront payments, milestone payments based on the achievement of specific clinical or regulatory milestones, and royalties from product sales once the therapies are commercialized. Additionally, Monte Rosa may benefit from research grants or funding from private or public institutions to support its R&D activities.

Monte Rosa Therapeutics Financial Statement Overview

Summary

Monte Rosa Therapeutics shows improvement in cash flow and revenue introduction, yet struggles with profitability, relying heavily on financing activities. A stable balance sheet provides some financial protection.

Income Statement

Monte Rosa Therapeutics experienced positive revenue generation in the latest year with a gross profit margin of 100% as revenue equaled gross profit. However, the company continues to face challenges with negative EBIT and net income, affecting its profitability. Despite the introduction of revenue, the net profit margin remains negative, indicating ongoing financial challenges.

Balance Sheet

The company's debt-to-equity ratio is moderate, reflecting a balanced approach to leveraging debt. However, the return on equity remains negative due to persistent net losses. A significant portion of the company's assets is funded by equity, as indicated by a stable equity ratio, which provides a buffer against financial risks.

Cash Flow

Monte Rosa Therapeutics has shown improvement in operating cash flow, turning positive from negative in the previous year. There is a noticeable improvement in free cash flow, indicating better cash management. However, cash flow from operations is still reliant on financing activities, reflecting dependency on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	181.54M	75.62M	0.00	0.00	0.00	0.00
Gross Profit	179.44M	67.50M	-6.22M	-8.56M	0.00	-537.00K
EBITDA	19.56M	-72.99M	-137.09M	-108.64M	-70.75M	-27.47M
Net Income	20.95M	-72.70M	-135.35M	-108.50M	-73.96M	-35.88M
Balance Sheet
Total Assets	459.84M	438.73M	303.75M	342.39M	366.33M	49.38M
Cash, Cash Equivalents and Short-Term Investments	391.26M	372.15M	232.41M	262.83M	346.07M	41.70M
Total Debt	40.17M	42.72M	46.04M	47.00M	0.00	67.76M
Total Liabilities	214.00M	215.80M	124.50M	70.98M	18.81M	98.11M
Stockholders Equity	245.84M	222.94M	179.25M	271.41M	347.51M	-48.73M
Cash Flow
Free Cash Flow	145.02M	38.01M	-62.84M	-105.38M	-69.09M	-26.44M
Operating Cash Flow	149.14M	42.00M	-43.80M	-92.47M	-59.36M	-23.05M
Investing Cash Flow	-67.66M	-44.45M	88.80M	-219.22M	-9.65M	-3.39M
Financing Cash Flow	1.33M	98.89M	27.49M	20.47M	377.56M	60.06M

Monte Rosa Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLUE, the sentiment is Positive. The current price of 24.08 is above the 20-day moving average (MA) of 19.24, above the 50-day MA of 16.93, and above the 200-day MA of 8.56, indicating a bullish trend. The MACD of 2.29 indicates Negative momentum. The RSI at 67.72 is Neutral, neither overbought nor oversold. The STOCH value of 84.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GLUE.

Monte Rosa Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLUE	75 Outperform	$1.84B	77.64	9.28%	―	1112.27%	―
CTMX	63 Neutral	$720.10M	12.89	66.76%	―	-10.26%	144.62%
FULC	53 Neutral	$684.77M	-8.60	-31.21%	―	-100.00%	-305.92%
MNPR	53 Neutral	$461.57M	-20.36	-26.54%	―	―	-73.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INBX	49 Neutral	$1.04B	-7.06	-144.07%	―	―	―

Monte Rosa Therapeutics Corporate Events

Monte Rosa Therapeutics Prices $300 Million Public Offering

On January 8, 2026, Monte Rosa Therapeutics priced a $300 million underwritten public offering comprising 11,125,000 shares of common stock at $24.00 per share and pre-funded warrants for 1,375,000 additional shares at $23.9999 per warrant, with underwriters granted a 30-day option to purchase up to 1,875,000 more shares. The deal, sold entirely by the company and expected to close on or about January 12, 2026, should generate approximately $281.6 million in net proceeds, which Monte Rosa plans to use, alongside existing cash and marketable securities, to advance its MRT-8102 program in chronic inflammatory diseases including atherosclerotic cardiovascular disease, further develop and deploy its QuEEN platform for additional molecular glue degraders in immunology, inflammation and oncology, and fund working capital and general corporate purposes; as a result of the capital raise, the company now expects its cash runway to extend into 2029, bolstering its financial position as it progresses three clinical programs and seeks to strengthen its leadership in the emerging MGD therapeutic space.

The most recent analyst rating on (GLUE) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Monte Rosa Therapeutics stock, see the GLUE Stock Forecast page.

Monte Rosa Therapeutics Ends Current ATM Equity Program

Effective January 7, 2026, Monte Rosa Therapeutics, Inc. terminated the sales agreement prospectus tied to its at-the-market equity offering program under its existing registration statement, meaning it will no longer sell common stock under that prospectus unless and until it files new offering documents, while the underlying Sales Agreement with Jefferies LLC remains in force. By the time of the termination, the company had issued and sold 2,955,082 shares of common stock through the program, raising aggregate net proceeds of $24.2 million, signaling a pause in at-the-market equity issuance that could affect its near-term financing flexibility and capital-raising strategy.

The most recent analyst rating on (GLUE) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Monte Rosa Therapeutics stock, see the GLUE Stock Forecast page.

Monte Rosa reports positive Phase 1 data for MRT-8102

On January 7, 2026, Monte Rosa Therapeutics reported positive interim results from a Phase 1 trial of its NEK7-directed molecular glue degrader MRT-8102 in healthy volunteers and subjects with elevated cardiovascular disease (CVD) risk, showing rapid, deep and sustained NEK7 degradation of around 80–90% across single and multiple ascending dose cohorts and in a Part 3 cohort. As of the December 23, 2025 data cutoff, four weeks of MRT-8102 treatment in 24 high‑risk CVD subjects reduced high-sensitivity C-reactive protein (hsCRP) by 85%, with 94% of participants achieving hsCRP levels below 2 mg/L, alongside marked suppression of IL‑1β and IL‑6, including a 55% median IL‑6 reduction in high‑CRP subjects and notable cerebrospinal fluid IL‑6 decreases in two participants, while maintaining a favorable safety profile with only mild to moderate, self-resolving adverse events and no signal of increased infection risk; the strength of these inflammation and biomarker data underpins Monte Rosa’s plans to advance MRT‑8102 into broader development for atherosclerotic cardiovascular disease and other NLRP3/IL‑1/IL‑6‑driven inflammatory conditions, and supports its broader molecular glue degrader pipeline in both immunology and oncology.

The most recent analyst rating on (GLUE) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Monte Rosa Therapeutics stock, see the GLUE Stock Forecast page.

Monte Rosa Reports Positive Phase 1/2 Study Results

On December 16, 2025, Monte Rosa Therapeutics announced positive interim results from its Phase 1/2 clinical study of MRT-2359 combined with enzalutamide in heavily pretreated metastatic castration-resistant prostate cancer patients. The study showed a 100% PSA response rate in patients with androgen receptor mutations, and the combination treatment maintained a favorable safety profile. The company plans to initiate a Phase 2 study in 2026 to further assess MRT-2359’s efficacy, potentially expanding the study to include additional patient subsets.

The most recent analyst rating on (GLUE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Monte Rosa Therapeutics stock, see the GLUE Stock Forecast page.

Monte Rosa Announces Q3 Results and Novartis Collaboration

On November 6, 2025, Monte Rosa Therapeutics announced its third-quarter financial results and business updates, highlighting a strong cash position expected to fund operations through 2028. The company signed a second collaboration agreement with Novartis to develop novel degraders for immune-mediated diseases, securing an upfront payment of $120 million and potential total deal value of up to $5.7 billion. Monte Rosa is advancing multiple clinical programs, including MRT-8102 for inflammatory diseases and MRT-6160 for immune-mediated conditions, with significant progress in oncology treatments like MRT-2359 for prostate cancer. The company’s strategic collaborations and clinical advancements underscore its growing impact in the biotechnology sector.

The most recent analyst rating on (GLUE) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Monte Rosa Therapeutics stock, see the GLUE Stock Forecast page.